Reporting guideline provided for? (i.e. exactly what the authors state in the paper)
Reporting of trials and trial protocols that undergo important modifications in response to extenuating circumstances.
Full bibliographic reference
Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan AW; CONSERVE Group. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. JAMA. 2021.
Language
English
PubMed ID
Relevant URLs (full-text if available)
The full-text of the CONSERVE 2021 Statement is freely available.
The authors have developed an implementation tool and two reporting checklists for CONSERVE which are included as a supplement to the journal article.
Reporting guideline acronym
CONSERVE
Study design
Clinical trials, Experimental studies, Study protocols
Applies to the whole report or to individual sections of the report?
Whole report
Additional information
The CONSERVE 2021 Statement is an extension to both the CONSORT and SPIRIT Statements.
Record last updated on
October 1, 2021
Training
The UK EQUATOR Centre runs training on how to write using reporting guidelines.